The combination of DcR3 siRNA with TRAIL or gemcitabine greatly enhances the apoptotic process in vitro and slows tumor growth in vivo, suggesting that the downregulation of extracellular antiapoptotic DcR3 may enhance anticancer therapy. Here, TNFSF10 is linked to neoplasm.